text_1: Therapeutics receiving accelerated approval encounter a lower frequency of post-marketing safety events
text_2: Objectives To characterize the frequency of postmarket safety events among novel therapeutics approved by the US Food and Drug Administration (FDA), and to examine whether any novel therapeutic characteristics known at the time of FDA approval were associated with increased risk.